Inhibikase Therapeutics (NASDAQ:IKT) Upgraded at Lifesci Capital

Lifesci Capital upgraded shares of Inhibikase Therapeutics (NASDAQ:IKT) to a strong-buy rating in a report issued on Monday,Zacks.com reports.

Several other research firms have also weighed in on IKT. Zacks Research upgraded shares of Inhibikase Therapeutics to a “hold” rating in a report on Tuesday, December 2nd. Wall Street Zen raised shares of Inhibikase Therapeutics to a “sell” rating in a research note on Saturday, December 27th. Cantor Fitzgerald upgraded shares of Inhibikase Therapeutics to a “strong-buy” rating in a report on Thursday, December 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research note on Thursday, January 22nd. Finally, HC Wainwright raised shares of Inhibikase Therapeutics to a “strong-buy” rating in a research report on Friday, December 26th. Three research analysts have rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy”.

Inhibikase Therapeutics Trading Up 4.4%

Inhibikase Therapeutics stock opened at $2.14 on Monday. Inhibikase Therapeutics has a 12 month low of $1.33 and a 12 month high of $2.58. The stock has a 50 day moving average of $1.74. The stock has a market cap of $160.89 million, a price-to-earnings ratio of -5.49 and a beta of 0.84.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.